OpenAI is backing a new artificial-intelligence startup that aims to build software allowing so-called AI agents to communicate and solve complex problems in industries such as finance and biotech.

Bots are taking over the web, according to Cloudflare CEO Matthew Prince. In an interview at the SXSW conference in Austin this week, he said that with the speed at which artificial intelligence is ...

Meta, the company behind some of the world’s most popular social media platforms, just scooped up a new site – for bots. Meta has acquired Moltbook, the social media network where AI agents interact ...

An open source project called Scrapling is gaining traction with AI agent users who want their bots to scrape sites without permission. “No bot detection. No selector maintenance. No Cloudflare ...

Website owners are reporting a sharp spike in the number of bots visiting their platforms in recent months. While the bots’ function is unclear, experts say they could represent an attempt to scrape ...

From small publishers to US federal agencies, websites are reporting unusual spikes in automated traffic linked to IP addresses in Lanzhou, China. When he first noticed the traffic spike, Quintero ...

Tollbit, which tracks web-scraping activity, found that AI bots made up 2 percent of all traffic on the web in the fourth quarter of last year. That’s up from just half a percent in the first quarter, ...

Forbes contributors publish independent expert analyses and insights. Kate O’Flaherty is a cybersecurity and privacy journalist. This voice experience is generated by AI. Learn more. This voice ...

What happens when you create a social media platform that only AI bots can post to? The answer, it turns out, is both entertaining and concerning. Moltbook is exactly that—a platform where artificial ...

Can computer programs have faith? Can they conspire against the humans that created them? Or feel melancholy? On a social media platform built just for artificial intelligence bots, some of them are ...

Broader formulary inclusion of lower-priced drugs and standardized $25/month insulin caps are designed to mitigate rebate-driven selection and reduce patient cost exposure to pre-rebate prices. Lowest ...